(Q34712716)

4 August 2017

1 reference

title

Neutralizing antibodies against HIV -- back in the major leagues? (English)

1 reference

4 August 2017

1 reference

Flavia Ferrantelli

1

1 reference

PubMed ID

12088685

4 August 2017

Ruth M Ruprecht

series ordinal

2

1 reference

4 August 2017

1 August 2002

1 reference

Current Opinion in Immunology

4 August 2017

1 reference

4 August 2017

14

1 reference

4 August 2017

4

1 reference

4 August 2017

495-502

1 reference

Antibody-dependent cellular cytotoxicity in HIV infections.

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Passive immunity in prevention and treatment of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Viral persistence: HIV's strategies of immune system evasion

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Prevention of HIV infection by passive immunization with HIV immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Passive immunization of macaques against SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Passive immunization of rhesus macaques against SIV infection and disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Role of complement and Fc receptors in the pathogenesis of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Prospects for vaccine protection against HIV-1 infection and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Clinical trials of HIV vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Deceptive imprinting in the immune response against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Mechanisms of viral membrane fusion and its inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2802%2900362-X

7 January 2021

10.1016/S0952-7915(02)00362-X

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12088685